ArticleTransfusion medicine (Oxford, England)2026
Characterisation of RHD and RHCE variations in blood donors from Jazan Province, Southwestern Saudi Arabia.
Article in Transfusion medicine (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesRh is among the most important and highly polymorphic blood group systems due to the proximity of the RHD and RHCE genes, which encode numerous highly immunogenic antigens. However, in areas of Saudi Arabia with a high prevalence of hemoglobinopathy, the molecular characteristics of RHD and RHCE variations are lacking. This study focuses on characterizing the allelic and genotypic distributions of RHD and RHCE blood donors in Jazan, Saudi Arabia. MATERIALS AND
methodsAll blood donors' records between June 2023 and December 2024 were reviewed. ID RHD XT was applied for 60 negative or weak RhD Saudi donors, while 354 Saudi and 110 non-Saudi donors received RHCE genotyping using the ID CORE XT.
resultsRHD deletion accounted for 76.7% of the RhD-negative donors. RHCE*Ce (44.1%) was the most common RHCE allele in Saudis, followed by RHCE*ce (31.9%) and RHCE*cE (12.3%). Variant alleles including RHCEce*(733G), RHCEce*(733G,1006T), RHCE*ceAR, RHCE*ce(712G), and RHDr's-RHCE*ce(733G,1006T) were detected in 11.72% in Saudi and 7.73% in non-Saudi, while low- and high-frequency antigens V, hrS, VS, and hrB were observed in Saudis with frequencies of 21.8%, 97.8%, 24.8%, and 93.2%, respectively. RHCE*ce/RHCE*Ce was the most prevalent genotype (26.8%). The non-Saudi group displayed similar profiles, with RHCE*Ce (48.2%), RHCE*ce (30.9%), and RHCE*cE (13.2%). There were no significant differences between Saudi and non-Saudi allele or genotype distributions using Fisher's exact test.
conclusionThe study represents the first molecular characterisation of RHD and RHCE alleles in Saudi Arabia, revealing marked allelic and genotypic diversity, with important implications for transfusion safety in the Jazan region, where hemoglobinopathies are prevalent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.